"Xolair: FDA-Approved Treatment for Severe Food Allergies"
The FDA has approved the antibody drug omalizumab (Xolair) as an injection to reduce allergic reactions to food in people aged 1 and up. In a trial, participants who received omalizumab were more likely to tolerate allergy-inducing foods compared to those who received a placebo. The drug works by binding to immunoglobulin E (IgE) antibodies involved in allergic responses. While it won't eliminate food allergies, it can reduce the health impact of accidental exposure. Side effects include injection site reactions, fever, joint pain, rash, and the possibility of other infections and malignancies.